PURPOSE: In clinical practice maximizing oxygen saturation in patients with high oxygen requirements without altering the appearance of the standard nasal cannula should improve adherence and functional outcomes. Our purpose was to compare the standard pulse dose oxygen delivery devices worn by marginally oxygenated patients with a newer generation device, the Eclipse 3 (E3).
METHODS: Seven patients with severe lung disease, Stage IV COPD or pulmonary fibrosis showed marginal saturations either at rest or with activity with their pulse dose equipment set on maximum flow. They were active and still attending group exercise at our pulmonary rehabilitation center. The Clinical Oxygen Dose Recorder (CODR) was used to monitor SPO2, heart rate and respiratory rate. For each patient a baseline was established using their existing long term oxygen therapy (LTOT) device and the Eclipse 3 (at a setting of 128 ml or 160 ml with medium and fast pulse dose duration) at rest and during activity consisting of walking at an even pace around a 36 foot oval course 2 to 3 times as tolerated. Individuals did not carry any of the equipment during the walk sessions.
RESULTS: Five patients attained a higher resting oxygen saturation level when using the E3 and two attained a saturation level comparable to their existing device. All individuals exhibited a higher activity oxygen saturation level when using the E3 as compared to their existing device, appeared to require less time to recover from the walk, and felt that the delivery of the larger bolus volume from the E3 was no less comfortable when compared to their usual device.
CONCLUSION: Marginally oxygenated patients on maximal pulse dose nasal cannula therapy may benefit from newer portable oxygen delivery systems that deliver a larger oxygen bolus rapidly, such as the Eclipse 3.
CLINICAL IMPLICATIONS: Having effective oxygen delivery devices available for patients who require higher doses of oxygen may improve adherence and activity status.
DISCLOSURE: Mary Hart, No Financial Disclosure Information; No Product/Research Disclosure Information